Finch Therapeutics Group, Inc., (FNCH) Social Stream
Finch Therapeutics Group Inc (FNCH) Price Targets From Analysts
Use the tables below to see what analysts covering Finch Therapeutics Group Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
FNCH's average price target has moved up $0.67 over the prior 32 weeks.
FNCH reports an average of 129.41% for its upside potential over the past 45 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
FNCH Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 120 days, FNCH's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for FNCH as an investment opportunity.
- In the context of all US stocks, Finch Therapeutics Group Inc's upside potential (average analyst target price relative to current price) is higher than 192.76% of them.
- To contextualize these metrics, consider that out of all US stocks, Finch Therapeutics Group Inc's number of analysts covering the stock is higher than 22.28% of them.
- In the context of Pharmaceutical Products stocks, Finch Therapeutics Group Inc's variance in analysts' estimates is lower than 60.54% of them.
- FNCH has a higher average analyst price target than 135.17% of stocks in the small market cap category.
In the Pharmaceutical Products industry, FDMT, ERYP, and ELEV are the three stocks most similar to Finch Therapeutics Group Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for FNCH? Use POWR Ratings for clearer insight into price direction.